Markowska Anna, Sajdak Stefan, Markowska Janina, Huczyński Adam
Department of Perinatology and Women's Diseases, Karol Marcinkowski Medical University in Poznan, Poland.
Department of Gynecological Surgery, Karol Marcinkowski Medical University in Poznan, Poland.
Eur J Med Chem. 2017 Dec 15;142:87-94. doi: 10.1016/j.ejmech.2017.06.030. Epub 2017 Jun 20.
Failure in ovarian cancer therapy, following cytoreduction and chemotherapy, is related to the presence of cancer stem cells - a small subpopulation of cells resistant to chemotherapy and irradiation - in the tumour which may cause cancer relapse and manifestation of metastases. Therapies targeted at Cancer Stem Cells (CSCs), such as those employing metformin (a drug used in the treatment of diabetes type II) and salinomycin, an antibiotic isolated from Streptococcus albus bacteria, seem promising. Anti-angiogenic therapy with bevacizumab was found to be effective in all phases of ovarian cancer treatment. The presence of CSCs has been associated with angiogenesis. Several CSC biomarkers correlate with the markers of angiogenesis and some signalling pathways, e.g. Notch, and are used by both CSCs and by pro-angiogenic factors.
在卵巢癌进行细胞减灭术和化疗后治疗失败，与肿瘤中癌症干细胞（一小部分对化疗和放疗有抗性的细胞亚群）的存在有关，这些癌症干细胞可能导致癌症复发和转移的出现。针对癌症干细胞（CSCs）的疗法，如使用二甲双胍（一种用于治疗II型糖尿病的药物）和盐霉素（一种从白色链霉菌中分离出的抗生素）的疗法，似乎很有前景。发现使用贝伐单抗的抗血管生成疗法在卵巢癌治疗的各个阶段均有效。癌症干细胞的存在与血管生成有关。几种癌症干细胞生物标志物与血管生成标志物以及一些信号通路（如Notch）相关，并且癌症干细胞和促血管生成因子都使用这些标志物。
